## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.42 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (44% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($170.39)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?**
- Source: TradingView â€” Track All Markets | 20251224T140823 | Somewhat-Bullish | Relevance: 100%
- Quest Diagnostics (DGX) is considered a good investment due to strategic acquisitions, advanced diagnostics, and cost management. However, concerns exist regarding its debt levels and macroeconomic challenges. The company has shown strong earnings performance, beating estimates consistently.

**2. Harbor Capital Advisors Inc. Has $596,000 Stake in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251228T111115 | Neutral | Relevance: 100%
- Harbor Capital Advisors Inc. reduced its stake in Quest Diagnostics (NYSE:DGX) by 71% in the third quarter, now holding 3,128 shares valued at $596,000. Despite this, other institutional investors have increased their positions, with collectively 88.06% of the stock owned by institutional investors and hedge funds. Quest Diagnostics surpassed Q3 earnings expectations, reporting EPS of $2.60 against an anticipated $2.51, and revealed intentions to pay a quarterly dividend of $0.80 per share.

**3. Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms**
- Source: ts2.tech | 20251225T211559 | Neutral | Relevance: 84%
- Abbott Laboratories (ABT) is ending 2025 with significant developments, including FDA approval for its Volt PFA system for AFib treatment, an expansion of its Lingo biowearable to Android, and a planned $23 billion acquisition of Exact Sciences to boost its diagnostics segment. However, the company is also navigating an FDA early alert regarding incorrect low glucose readings from some FreeStyle Libre 3/3 Plus sensors. Analysts remain broadly constructive on ABT, with a consensus 12-month price target around $147, as the company layers new products and strategic M&A onto a solid growth base while managing product-related risks.

**4. Revenue Cycle Management (RCM) Market Overview, Key Growth Factors, and Major Player Analysis**
- Source: openPR.com | 20251224T160945 | Somewhat-Bullish | Relevance: 81%
- The Revenue Cycle Management (RCM) market is projected to reach $273.6 billion by 2029, growing at a CAGR of 15.1%, driven by technological advancements and evolving healthcare models. Key trends include the integration of AI, machine learning, and blockchain, along with a focus on value-based care and patient engagement. The market features significant players like R1 RCM Inc. and McKesson Corporation, with recent strategic acquisitions and technological innovations further shaping its landscape.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 5 ($3.52M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $3.5M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.42 suggests fair value with growth premium. Forward P/E 17.0x stretched relative to 6% growth. Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.42 |
| Forward P/E | 17.0 |
| Current P/E | 17.9 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+1.0% over 5 days). Below STRENGTH zone by 7.3pp (needs >4.0% for momentum thesis). Underperforming sector by 3.9pp, stock-specific weakness. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram bearish (-0.62), momentum weakening. Volume at 44% of 20MA suggests lack of conviction. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.34% (CS: 17) | Weak |
| RSI_14 | 38.0 | Neutral |
| MACD Histogram | -0.62 | Bearish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 0.964x | Below |
| vs SMA200 | 0.993x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $175.97
- **Stop Loss:** $170.39 (3.2% risk)
- **Target:** $187.13 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 236
- **Position Value:** $41,528.92
- **Portfolio %:** 41.53%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*